Head-to-head evidence
EDP167 vs Evinacumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
EDP167
Developed by Eddingpharm (Zhuhai) Co., Ltd.
NCT07412080 · Phase 1 · completed
Participants were randomized to active drug or placebo with full blinding maintained, but the primary endpoint is safety and tolerability rather than a lipid or cardiovascular outcome, and results are not yet posted, so its eventual finding is unknown.
Next expected readout: November 2027 · NCT07799129 (registry estimate)
Evinacumab · Evkeeza
Marketed by Regeneron Pharmaceuticals
NCT03399786 · Phase 3 · completed
The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: EDP167's landscape · Evinacumab's landscape